2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

2:30PM-4:00PM: Abstract Number: 3040

Th17 Migration into the Synovial Fluid of Patients with Active Psoriatic Arthritis Is Enhanced By Regulatory T Cells

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology I

2:30PM-4:00PM: Abstract Number: 3018

The Analysis of Severity of Arthritis in the Intestinal Microbiota-Humanized Mice

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 3004

The Choosing Wisely Initiative: Is It Complete?

Orthopedics, Low Back Pain and Rehabilitation

2:30PM-4:00PM: Abstract Number: 3025

The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Small Molecules and Early Intervention

2:30PM-4:00PM: Abstract Number: 3026

The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy III: Small Molecules and Early Intervention

2:30PM-4:00PM: Abstract Number: 3015

The Good, the Bad and the Ugly – Refractory Rheumatoid Arthritis in 2016

Rheumatoid Arthritis – Clinical Aspects IV: Managing Patients in Remission

2:30PM-4:00PM: Abstract Number: 3029

Ultrasonography of Major Salivary Glands in Patients Suspected with Primary Sjögren’s Syndrome: Comparison with Salivary Gland Biopsy and Classification Criteria

Sjögren's Syndrome I: Clinical Insights

2:30PM-4:00PM: Abstract Number: 3016

Validity of a 2-Component Disease Activity Score for Accurate Assessment of Synovitis in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects IV: Managing Patients in Remission

2:30PM-4:00PM: Abstract Number: 2995

WISP1/CCN4 Aggravates Experimental Osteoarthritis and Is Associated with Disease Progression in Early Osteoarthritis Patients

Biology and Pathology of Bone and Joint

4:30PM-6:00PM: Abstract Number: 3106

A Simple Test for Assessing and Monitoring SLE Disease Activity Status

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3103

Apolipoprotein L1 Risk Variants Associate with Prevalent Cardiovascular Disease in African American Systemic Lupus Erythematous Patients

Systemic Lupus Erythematosus – Clinical Aspects and Treatment IV: Biomarkers

4:30PM-6:00PM: Abstract Number: 3096

Association Between Smoking and Psoriatic Arthritis Among Psoriasis Patients and the General Population: Data from National Inpatient Sample

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV: Psoriatic Arthritis – Clinical

4:30PM-6:00PM: Abstract Number: 3087

Association of Weight Loss with Improved Disease Activity in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects V: Challenges in the Assessment and Management of Established RA

4:30PM-6:00PM: Abstract Number: 3100

Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Prospective Cohort Study in Psoriatic Arthritis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV: Psoriatic Arthritis – Clinical

4:30PM-6:00PM: Abstract Number: 3053

Cartilage Loss Primarily Occurs in the Most Affected Tibiofemoral Compartment with No Evidence of a Ceiling Effect Among Advanced-Stage Disease: A Two-Year Longitudinal Study of Data from the Osteoarthritis

ACR/ARHP Combined Abstract Session: Orthopedics and Rehabilitation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].